Results

1–10 of 10 results for solution

Rapid Fluid Resolution With Aflibercept 8 mg May Be Associated With Extended Dosing Intervals at Week 96 in nAMD: A PULSAR Post Hoc Analysis
Michael W. Stewart, MD
Annual Meeting Talks
2025
Baseline and Early Treatment Response Variables Associated With Faricimab Durability in Treatment-Naive nAMD: TENAYA/LUCERNE Post Hoc Analyses
Benjamin Bakall, MD, PhD
Annual Meeting Talks
2025
Surgical Case Conference: Jayant Kumar, MBBS, MS, DNB, MNAMS, FICO, FVRS
Annual Meeting Talks
2024
Phentolamine Ophthalmic Solution Rapidly Reverses Pharmacologically Induced Mydriasis in Two Pivotal Phase 3 MIRA Trials
David S. Boyer, MD
Annual Meeting Talks
2022
Baseline Factors Influencing Diabetic Macular Edema (DME) Resolution After Intravitreal Aflibercept Injection (IAI) or Laser Treatment in VISTA/VIVID
W. Lloyd Clark, MD, FASRS
Annual Meeting Talks
2021
Baseline DR Severity and Time to DME Resolution in Patients Treated With Ranibizumab in the RIDE and RISE Clinical Trials
Katherine E Talcott, MD
Annual Meeting Talks
2021
Phentolamine Ophthalmic Solution Rapidly Reverses Pharmacologically Induced Mydriasis in Two Pivotal Phase 3 MIRA Trials
David S. Boyer, MD
Updates from the Field
2022
Abicipar for nAMD Provides Faster Retinal Fluid Resolution, and Achieved Similar Dryness Through Week 104 With Fewer Injections
Nancy M. Holekamp, MD, FASRS
Annual Meeting Talks
2020
Adjunctive Focal Laser Following Central Fluid Resolution After Bevacizumab, Ranibizumab, or Aflibercept Injection: A Secondary Analysis of Protocol T
Jennifer R Gallagher, MD
Annual Meeting Talks
2020
Effect of Baseline Ocular Characteristics on Vitreomacular Adhesion/Vitreomacular Traction Resolution With Ocriplasmin: ORBIT Study Subanalysis
David S. Boyer, MD
Annual Meeting Talks
2018